Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Retained Earnings (2023 - 2025)

Connect Biopharma Holdings' Retained Earnings history spans 3 years, with the latest figure at -$385.7 million for Q3 2025.

  • For Q3 2025, Retained Earnings changed N/A year-over-year to -$385.7 million; the TTM value through Sep 2025 reached -$385.7 million, changed N/A, while the annual FY2024 figure was -$1.7 million, 65.28% down from the prior year.
  • Retained Earnings for Q3 2025 was -$385.7 million at Connect Biopharma Holdings, down from -$368.5 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$1.0 million in Q4 2023 and bottomed at -$385.7 million in Q3 2025.
  • The 3-year median for Retained Earnings is -$355.6 million (2025), against an average of -$222.5 million.
  • The largest YoY upside for Retained Earnings was 65.28% in 2024 against a maximum downside of 65.28% in 2024.
  • A 3-year view of Retained Earnings shows it stood at -$1.0 million in 2023, then tumbled by 65.28% to -$1.7 million in 2024, then crashed by 23052.82% to -$385.7 million in 2025.
  • Per Business Quant, the three most recent readings for CNTB's Retained Earnings are -$385.7 million (Q3 2025), -$368.5 million (Q2 2025), and -$355.6 million (Q1 2025).